Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation.
| Autor: | Sawyer J; Pharmacy VA Tennessee Valley Healthcare System., Elliott T; Pharmacy VA Tennessee Valley Healthcare System., Orton L; Pharmacy Vanderbilt University Medical Center., Sowell H; Pharmacy Vanderbilt University Medical Center., Gatwood K; Pharmacy Vanderbilt University Medical Center., Shultes K; Pharmacy VA Tennessee Valley Healthcare System. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical hematology international [Clin Hematol Int] 2024 Apr 03; Vol. 6 (2), pp. 1-10. Date of Electronic Publication: 2024 Apr 03 (Print Publication: 2024). |
| DOI: | 10.46989/001c.94952 |
| Abstrakt: | Hematopoietic stem cell transplantation (HSCT) remains the only curative option for several hematological malignancies. Its use has continued to grow, with an estimated 23,500 transplants performed annually in the United States alone. The acute toxicities that occur from conditioning chemotherapy can impact the peri-transplant period and have substantial implications on patients' tolerability and outcomes, irrespective of the treatment of their disease. Chemotherapy-induced nausea vomiting (CINV), mucositis, transplant-associated thrombotic microangiopathy (TA-TMA), and sinusoidal obstruction syndrome, also known as a veno-occlusive disease (SOS/VOD) can all have significant implications for patients. These acute complications begin with the start of conditioning chemotherapy and add to potential toxicity for patients throughout the early post-transplant period, from Day +30 for CINV, mucositis, and SOS, and which can continue through at least Day +100 with the onset of TA-TMA. These toxicities must be prevented and managed appropriately. This review will summarize the literature surrounding them and guide their management. Competing Interests: Katie Gatwood has received a speaker honorarium from Jazz Pharmaceuticals. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|